Select language:

The Lancet: Sputnik Light is effective and safe for patients

 / Главная / Russkiy Mir Foundation / News / The Lancet: Sputnik Light is effective and safe for patients

The Lancet: Sputnik Light is effective and safe for patients


03.11.2021

Photo by M. Mishin. Press service of the Mayor and Government of Moscow / mos.ru (CC BY 4.0)

The Lancet medical journal has published the results of phase I and II trials for the Russian Sputnik Light vaccine, TASS reports. The drug show a high safety profile and induced a humoral and cellular immune response.

The research was sponsored by the Russian Direct Investment Fund. Scientists noted that no serious adverse events had been identified. Most of the adverse reactions were mild to moderate.

Sputnik Light is a one-component vaccine approved for clinical use in Russia. It has demonstrated high efficiency both when used independently and as a boosting injection. The vaccine has been registered in more than 15 countries. In another 30 countries, the registration is underway. 

Earlier, the Gamaleya Center, which developed the drug, noted that with separate use, the effectiveness of the drug reaches 70%  against the delta strain within three months after vaccination. In the age group under 60, the vaccine is at least 75% effective.

Russkiy Mir

News by subject

Publications

Marco Maggi: ”Russian to the Bone" 20.01.2024
Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core.